"The FDA says the drug may only be given to people aged 9 through 16 who have laboratory-confirmation of a previous dengue infection and live in areas where the disease is prevalent, such as Puerto Rico, the U.S. Virgin Islands and American Samoa. "
wow. Ito yung exact observation ng pedia namin. Nung bagong labas ang dengue vaccine like 2 or three years ago, we asked her view on the vaccine. Kung recommended niya ba for our kids.
Sabi niya hindi muna kasi ang observation niya, effective siya sa mga taong nagka-dengue na.
napolitika kasi ang dengvaxia
naging duterte vs dilaw
pero totoo may problema ung dengue vaccine na yan
di pwede yan sa mga hindi pa nagka dengue
kaya noong nag clinical trial they only gave it to kids 9 yrs and up coz it's more likely that in dengue-prevalent countries by age 9 nagka dengue ka na
they can't test individually kung nagka dengue na coz it would be too costly
that's why they just set a minimum age pero syempre meron parin mga age 9 and up na di pa nagka dengue
Last edited by uls; July 17th, 2019 at 10:30 AM.
ang effect kasi ng vaccine na yan to dengue-naive people is their immune system mounts an over-the-top response and causes internal bleeding
May nag-offer na saakin nung ganyan klaseng injectables pero inayawan ko kasi yan yung peak nung issue noon. Natakot ako para sa sarili ko. Hahaha
(For the record, twice na ako nagkaroon ng dengue before i-offer saakin yung injectables..)
research after the fact confirms it.
the vaccine works, but only if it is administered to persons with the correct infectious background.
ang nakukuha ko kasi sa iba dito safe ang dengvaxia for everyone
pinolitika lang kasi Aquino admin project
pinalabas daw ng current admin na nakakamatay ang dengvaxia
pero if you just do a little reading, totoo ung exaggerated immune response ng dengue-naive when injected with dengvaxia
even sanofi admittted it
The way I understood it is there are about 3(?) strains of dengue. The vaccine works if the individual already got infected by dengue once before, in effect the vaccine acts as a booster. Subsequent infections will range from mild to full immunity.
The problem occurs when the vaccine is administered when one has not yet been infected previously and the dengue that "takes root" is a particularly virulent strain. There are likely physiological reactions and even deaths from the immunization but statistically no different from other vaccines. And most certainly not in the sensationalized views of Acosta et al.
i always tell my students,
"even if historical statistics are favorable, the same statistics are not acceptable, if it was your kid suffering from its ill-effects".
FDA approves the first vaccine for dengue fever, but with major restrictions
The Food and Drug Administration on Wednesday approved the first vaccine against dengue fever, one that protects against a common disease but has generated significant controversy due to evidence it can increase the risk of severe infection in some people.
The agency ruled that Dengvaxia, manufactured by Sanofi Pasteur, can only be used in individuals aged 9 to 16 living in parts of the United States where the dengue virus is endemic — in other words, where it circulates on an ongoing basis. Dengue is found only in Puerto Rico and a few other U.S. offshore territories and protectorates.
Furthermore, the vaccine can only be given to children and teens who have had one previous laboratory-confirmed case of dengue.
Regulators have sought to restrict access to Dengvaxia following post-marketing research by Sanofi that showed that, while the vaccine offers protection for people who have already had at least one bout of dengue, it increases the risk of severe infection in children who were dengue-naïve — that is, never infected — when they were vaccinated.
EVEN SANOFI admits di pwede ang dengvaxia sa dengue-naive
ginawa lang nilang malaking clinical trial ang Pinas
pero syempre para sa mga hardened anti-du30, this issue is pure politics
WHO | WHO advises Dengvaxia be used only in people previously infected with dengue
1st infection - minor symptomsThe WHO Global Advisory Committee on Vaccine Safety considered the company’s new results from clinical trial data analyses. Those studies indicate that increased risk of severe dengue disease in people who have never been infected affects about 15% of the vaccinated individuals. The magnitude of risk is in the order of about 4 out of every 1000 seronegative patients vaccinated who developed severe dengue disease during five years of observation. The risk of developing severe dengue disease in non-vaccinated individuals has been calculated as 1.7 per 1000 over the same period of observation. By contrast, for the 85% who have had dengue disease before immunization, there is a reduction of 4 cases of severe dengue per 1 000 who are vaccinated.
2nd infection and so on - severe dengue can happen. That's what the vaccine is supposed to prevent.
were these conditions already being mulled by the manufacturer and/or the researchers, even before the DOH approved its seeming-lightning-fast program?
or was it kept hush-hush, back then?
there were warnings already over ADE (antibody-dependent enhancement) but Sanofi played it down